Chemical formula: C₂₅H₃₄O₆ Molecular mass: 430.534 g/mol PubChem compound: 5281004
Budesonide is indicated for:
Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)
Treatment of persistent bronchial asthma in patients where use of a pressurised inhaler or dry powder formulation is unsatisfactory or inappropriate.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adults (18 years old or older)
Induction of remission in patients with mild to moderate active Crohn’s disease affecting the ileum and/or the ascending colon.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adults (18 years old or older)
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only children (1 year - 12 years old)
Treatment of persistent bronchial asthma in patients where use of a pressurised inhaler or dry powder formulation is unsatisfactory or inappropriate.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)
Very serious pseudocroup (laryngitis subglottica) in which hospitalisation is indicated.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)
Treatment and prevention of signs and symptoms of seasonal and perennial allergic rhinitis.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)
Treatment of signs and symptoms of nasal polyps.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adults (18 years old or older)
Induction of remission in patients with active collagenous colitis.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adults (18 years old or older)
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adults (18 years old or older)
For the treatment of active ulcerative colitis that is limited to the rectum and the sigmoid colon.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adults (18 years old or older)
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Budesonide is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
